Filter Results:
(925)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
- July 2010
- Case
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Cambridge Sciences Pharmaceuticals (CSP) expects final approval for its revolutionary weight loss drug, Metabical. Metabical will be the only weight loss drug with FDA approval that is also clinically proven to be effective for moderately overweight people. Barbara... View Details
Keywords: Product Positioning; Marketing Communications; Product Launch; Consumer Behavior; Pharmaceutical Industry; United States
Quelch, John A., and Heather Beckham. "Metabical: Positioning and Communications Strategy for a New Weight Loss Drug." Harvard Business School Brief Case 104-240, July 2010.
- October 2012
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
By: Toby Stuart and James Weber
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and James Weber. "Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)." Harvard Business School Case 813-029, October 2012.
- March 2008 (Revised June 2008)
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
- April 2008 (Revised May 2009)
- Case
Robert Wessman and Actavis' "Winning Formula"
Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with 11,000 people, active in 40 countries, global manufacturing, and $1.6 billion.... View Details
Keywords: Globalized Firms and Management; Business Growth and Maturation; Success; Transformation; Business Strategy; Pharmaceutical Industry; Iceland
Isenberg, Daniel J. Robert Wessman and Actavis' "Winning Formula". Harvard Business School Case 808-127, April 2008. (Revised May 2009.)
- July 1989 (Revised December 1990)
- Case
CIBA-GEIGY Pharmaceuticals: Pharma International
By: John A. Quelch
Examines the decision by Pharma International on whether to launch an antimalarial product in Nigeria and, if so, how that should be implemented. Involves commercial, ethical, and policy considerations. Rich in situation assessment data, the case refers to criticism of... View Details
Keywords: Ethics; Decision Choices and Conditions; Product Launch; Policy; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Quelch, John A. "CIBA-GEIGY Pharmaceuticals: Pharma International." Harvard Business School Case 589-108, July 1989. (Revised December 1990.)
- April 2014
- Case
Merrimack Pharmaceuticals, Inc. (A)
By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R＆D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
- January 2016 (Revised January 2019)
- Case
The Allergan Board Under Fire (A)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R＆D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Management Teams; Business and Shareholder Relations; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.)
- September 2012
- Case
SCMS: Battling HIV/AIDS in Africa
By: Ananth Raman, Noel Watson, Santiago Kraiselburd and Emmanuel Akili
In 2005, USAID and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), created the Supply Chain Management System (SCMS) to procure and distribute essential medicines and supplies; provide technical assistance to transform existing supply chains; and... View Details
Keywords: HIV; AIDS; Procurement Coordination; Developing Countries; Healthcare; Public Health; Ethiopia; Supply Systems For Healthcare Delivery In Developing Countries; Healthcare Logistics Industry; Health Disorders; Health Care and Treatment; Service Delivery; Supply Chain Management; Logistics; Developing Countries and Economies; Programs; Transition; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Ethiopia; Africa
Raman, Ananth, Noel Watson, Santiago Kraiselburd, and Emmanuel Akili. "SCMS: Battling HIV/AIDS in Africa." Harvard Business School Case 613-023, September 2012.
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R＆D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Corporate Governance; Investment Activism; Business and Stakeholder Relations; Business Model; Business and Shareholder Relations; Valuation; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
- November 2016 (Revised February 2017)
- Case
CVS Health: Redefining the Value Proposition
By: Michael E. Porter, Jorge Ramirez-Vallejo and Alexandra Houghtalin
This case explores how a company can use shared value as a lens to think about competition and strategy choices in a challenging and evolving industry. The case takes a historical look at the structure of the retail pharmacy industry and the changing nature of rivalry... View Details
Keywords: Shared Value; Pharmacy; Health Care; Strategy; Competitive Strategy; Retail Industry; Retail Industry; United States
Porter, Michael E., Jorge Ramirez-Vallejo, and Alexandra Houghtalin. "CVS Health: Redefining the Value Proposition." Harvard Business School Case 717-436, November 2016. (Revised February 2017.)
- June 2004
- Case
Aventis SA (A): Planning for a Merger
By: Joshua D. Margolis and Carin-Isabel Knoop
Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must... View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (A): Planning for a Merger." Harvard Business School Case 404-003, June 2004.
- December 2008 (Revised April 2010)
- Case
Proteus Biomedical: Making Pigs Fly
By: Richard G. Hamermesh, Lauren Barley and Ginger Graham
Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is... View Details
Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Health Industry; Health Industry; Health Industry
Hamermesh, Richard G., Lauren Barley, and Ginger Graham. "Proteus Biomedical: Making Pigs Fly." Harvard Business School Case 809-051, December 2008. (Revised April 2010.)
- November 2006
- Case
Selling Biovail Short
By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia
Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details
Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada
Baker, Malcolm P., Chris Lombardi, and Aldo Sesia. "Selling Biovail Short." Harvard Business School Case 207-071, November 2006.
- August 2013
- Teaching Plan
Remicade-Simponi
By: Guhan Subramanian and Charlotte Krontiris
This exercise models a negotiation between two pharmaceutical companies—Johnson & Johnson and Merck—concerning the international distribution rights for Remicade, a blockbuster anti-arthritis drug. At odds over the original distribution contract, the two companies... View Details
Keywords: Johnson ＆ Johnson; Merck; Negotiation; Negotiation Participants; Negotiation Deal; Pharmaceutical Industry
Subramanian, Guhan, and Charlotte Krontiris. "Remicade-Simponi." Harvard Business School Teaching Plan 914-006, August 2013.
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- January 2023 (Revised August 2023)
- Case
Veeva Systems and the Transformation to a Public Benefit Corporation
By: Ranjay Gulati and Allison M. Ciechanover
Peter Gassner, the co-founder and CEO of Veeva Systems, steered the company through rapid scaling from its launch in 2007 to 2022. Year after year, the company had exceeded expectations, with its market capitalization reaching $50 billion at its peak. By 2022, the... View Details
Keywords: Transformation; Corporate Governance; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Culture; Information Technology Industry; Information Technology Industry; United States; California
Gulati, Ranjay, and Allison M. Ciechanover. "Veeva Systems and the Transformation to a Public Benefit Corporation." Harvard Business School Case 423-045, January 2023. (Revised August 2023.)
- Research Summary
Regulatory negotiations and risk communication
In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details
- Research Summary
Entrepreneurial Finance and International R&D Management
Walter Kuemmerle's research and teaching interests fall within the domain of knowledge and capital management in a global economy. His research focuses on international entrepreneurship and venture capital. He studies venture capital systems and entrepreneurship in... View Details
- January 2001 (Revised May 2003)
- Case
Novartis Pharma: The Business Unit Model
By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis
In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details
Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Health Industry; Health Industry
Datar, Srikant M., Carin-Isabel Knoop, and Cate Reavis. "Novartis Pharma: The Business Unit Model." Harvard Business School Case 101-030, January 2001. (Revised May 2003.)
- August 2003 (Revised August 2006)
- Case
New Sector Alliance (A): An Entry into Health Care?
By: Regina E. Herzlinger, Stacy Smollin Schwartz and Jeffrey Cronin
Describes the structure of the U.S. health care system and presents a study of a nonprofit consulting firm that hopes to enter the health care system. Includes descriptions of hospitals, doctors, insurers, medical technology providers, medical devices, pharmaceuticals,... View Details
Keywords: Health; Health Care and Treatment; Health Disorders; Nonprofit Organizations; Health Industry; United States
Herzlinger, Regina E., Stacy Smollin Schwartz, and Jeffrey Cronin. "New Sector Alliance (A): An Entry into Health Care?" Harvard Business School Case 304-004, August 2003. (Revised August 2006.)